SynthesisBritish journal of clinical pharmacology2013
Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.
Synthesis in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Guideline
- Risk-Reducing Strategies for Ovarian Cancer inThe oncologist · 2017Pooled it
- Association between nonsteroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis.British journal of clinical pharmacology · 2014Pooled it
- Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.Journal of the National Cancer Institute · 2014Pooled it
- Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial.Journal of gynecologic oncology · 2016Trial
- Dual Actions of Ketorolac in Metastatic Ovarian Cancer.Cancers · 2019Review
- Epidemiology of ovarian cancer: a review.Cancer biology & medicine · 2017Article
- Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.Molecular cancer therapeutics · 2016Article
- Analgesic medication use and risk of epithelial ovarian cancer in African American women.British journal of cancer · 2016Article
- Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management.International journal of women's health · 2016Review
- Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.Oncotarget · 2015Article
- Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice.Clinical cardiology · 2015Review
- Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells.Journal of Cancer · 2013Article
- Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells.Cancer discovery · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAnimal and in vitro studies suggest that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk for ovarian cancer. However, results from these studies have been inconsistent. The aim of our study was to review and summarize the evidence provided by longitudinal studies on the association between NSAID use and ovarian cancer risk.
methodsA comprehensive literature search for articles published up to December 2011 was performed. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Relative risk (RR) or odds ratios (OR) were calculated.
resultsSeventeen reports (13 case-control studies, one clinical trial and three cohort studies), published between 1998 and 2011 were identified. There was no evidence of an association between aspirin use and ovarian cancer risk based on a random-effects model (RR = 0.91, 95% confidence interval (CI) 0.82, 1.01) or a fixed-effects model (RR = 0.94, 95% CI 0.87, 1.01). Similarly, we did not find strong evidence of an association between non-aspirin NSAID use and ovarian cancer using a random-effects model (RR = 0.89, 95% CI 0.74, 1.08) or a fixed-effects model (RR = 0.86, 95% CI 0.76, 0.98). Furthermore, our analysis did not show a strong association between frequency or duration of non-aspirin-NSAID use and ovarian cancer.
conclusionsOur findings indicate that there is no strong evidence of an association between aspirin/NA-NSAID use and ovarian cancer. However, this subject deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.